ctDNA After Surgery Identified Patients at High Risk for Early Recurrence in Stage III Melanoma Trial
Source: Oncology News Central, May 2025
Measurements of circulating tumor DNA (ctDNA) before adjuvant targeted therapy and during follow-up identified patients with stage III melanoma at high risk for early disease recurrence, according to results of an analysis of patients from the COMBI-AD trial published recently in The Lancet Oncology.
In addition, trial results “demonstrated the potential value of monitoring ctDNA levels over time,” said study researcher David Polsky, MD, PhD, professor of dermatology and pathology at the NYU Grossman School of Medicine in New York City.
“Although the test is not yet sensitive enough to identify all patients who will recur, in some patients the test was initially negative but then became positive while on treatment,” Dr. Polsky said. “We found that patients with molecular relapse inevitably recurred.”